A digital motor score for sensitive detection of disease progression in early manifest Huntington’s disease
The number of participants required for a clinical trial is directly related to how sensitively disease progression can be tracked. Huntington’s disease (HD) clinical trials often require large numbers of participants to sensitively track disease progression. This poster describes the sensitivity to change of the newly developed HD digital motor score (HDDMS), which combines selected features from the Roche HD digital monitoring platform, in people with HD-Integrated Staging System (HD-ISS) Stage 2 and Stage 3 HD, compared with the composite Unified Huntington’s Disease Rating Scale (cUHDRS).
You are Leaving Medically
By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.
You are Leaving the Global Medically Site
By following this link, you are being redirected to another Roche page.